# BCL6B

## Overview
BCL6B is a gene that encodes the BCL6B transcription repressor, a protein involved in the regulation of gene expression. This protein functions primarily as a transcriptional repressor, playing a crucial role in various biological processes, including tumor suppression, immune response modulation, and stem cell differentiation. BCL6B is particularly significant in the context of endothelial cell differentiation and immune system regulation, where it influences the expression of key factors involved in these processes (Xu2011Epigenetic; Li2024BCL6Bdependent). The protein interacts with several signaling pathways, such as Notch, STAT, and p53, which are essential for regulating cellular responses to inflammation and stress (Li2015Epigenetic; Cai2019Inhibition). Alterations in the expression of BCL6B, often through epigenetic modifications, have been linked to the progression of various cancers, highlighting its potential as a target for therapeutic interventions (Cai2019Inhibition; Xu2011Epigenetic).

## Function
BCL6B is a transcriptional repressor involved in various biological functions, including tumor suppression, immune response, and stem cell self-renewal. It acts primarily in the nucleus, where it binds to specific DNA sequences to repress transcription, influencing cellular processes such as cell proliferation and apoptosis (Xu2011Epigenetic). BCL6B is known to inhibit endothelial cell (EC) differentiation from human induced pluripotent stem cells (hiPSCs) by repressing the transcription of ETV2, a key factor in EC differentiation. During this process, BCL6B expression decreases while ETV2 expression increases, indicating a regulatory role in vascular development (Li2024BCL6Bdependent).

In healthy human cells, BCL6B is highly expressed at the mRNA level in human ECs, although its protein expression is low. Knockdown of BCL6B in hiPSCs increases EC differentiation, suggesting its role as a suppressor in this context (Li2024BCL6Bdependent). BCL6B also plays a role in the immune system, particularly in the secondary responses of memory CD8+ T cells, and its overexpression can induce apoptosis in certain cell types (Xu2011Epigenetic). These functions highlight BCL6B's involvement in critical cellular and organismal processes, including immune response modulation and vascular development.

## Clinical Significance
The BCL6B gene is implicated in various cancers, particularly gastric cancer (GC), where it functions as a tumor suppressor. In GC, BCL6B is often epigenetically silenced through promoter hypermethylation, leading to its downregulation. This silencing is associated with poor survival outcomes in patients, as BCL6B normally suppresses tumor growth and inflammation (Cai2019Inhibition; Xu2011Epigenetic). The demethylation drug 5-Aza can restore BCL6B expression, reducing tumor size and number in wildtype mice, but not in Bcl6b knockout mice, indicating the gene's critical role in mediating the drug's effects (Cai2019Inhibition).

In hepatocellular carcinoma (HCC), BCL6B is also frequently methylated, leading to its inactivation. This methylation is linked to the inactivation of p53 signaling, contributing to cancer cell resistance to treatments like 5-fluorouracil (Li2015Epigenetic). The loss of BCL6B expression in HCC is associated with increased cell proliferation and reduced apoptosis, highlighting its role in tumor suppression.

Overall, alterations in BCL6B expression, particularly through epigenetic modifications, are significant in the progression and prognosis of certain cancers, making it a potential target for therapeutic interventions.

## Interactions
BCL6B, a transcriptional repressor, is known to interact with various proteins and nucleic acids, playing a significant role in gene regulation. It binds to STAT6 binding sequences, thereby repressing gene activities induced by STAT proteins, indicating a direct interaction with specific DNA sequences (Zhang2019Expression). BCL6B also interacts with several signaling pathways, including Notch, STAT, p53, and PI3K/AKT, which are crucial in regulating inflammatory responses in cancer cells (Cai2019Inhibition). 

In the context of liver fibrosis, BCL6B regulates hepatocyte growth factor (HGF) expression, which is a potent anti-fibrotic cytokine. This regulation suggests an interaction with the signaling pathways that control HGF expression, although the exact physical interactions are not detailed (Wang2015BCL6B). In hepatocellular carcinoma (HCC), BCL6B modulates gene expression profiles related to metastasis, influencing the expression of cell adhesion genes and metastasis suppressors, while suppressing pro-angiogenic factors like VEGFA (Wang2014B). 

BCL6B's role in apoptosis and cell cycle regulation is linked to its ability to upregulate p53 and its downstream targets, such as p21 and caspases, while downregulating MDM2 and bcl-2, suggesting interactions within the p53 signaling pathway (Li2015Epigenetic).


## References


[1. (Zhang2019Expression) Runshuai Zhang, Xiaomei Ke, Kongyue Wu, Hao Shen, Emile Nibona, Abdullah Al Hafiz, Xiaoting Liang, Weiyuan Ye, Qingchun Zhou, Xueping Zhong, and Haobin Zhao. Expression of the alternative splicing variants of bcl6b in medaka oryzias latipes. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 227:83–89, January 2019. URL: http://dx.doi.org/10.1016/j.cbpb.2018.10.002, doi:10.1016/j.cbpb.2018.10.002. This article has 5 citations.](https://doi.org/10.1016/j.cbpb.2018.10.002)

[2. (Xu2011Epigenetic) Lixia Xu, Xiaoxing Li, Eagle S H Chu, Guijun Zhao, Minnie Y Y Go, Qian Tao, Hongchuan Jin, Zhirong Zeng, Joseph J Y Sung, and Jun Yu. Epigenetic inactivation ofbcl6b, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut, 61(7):977–985, September 2011. URL: http://dx.doi.org/10.1136/gutjnl-2011-300411, doi:10.1136/gutjnl-2011-300411. This article has 60 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/gutjnl-2011-300411)

[3. (Wang2014B) Jia Wang, Ling Dong, Lixia Xu, Eagle S.H. Chu, Yangchao Chen, Jiayun Shen, Xiaoxing Li, Chi Chun Wong, Joseph J.Y. Sung, and Jun Yu. B cell cll/lymphoma 6 member b inhibits hepatocellular carcinoma metastases in vitro and in mice. Cancer Letters, 355(2):192–200, December 2014. URL: http://dx.doi.org/10.1016/j.canlet.2014.08.025, doi:10.1016/j.canlet.2014.08.025. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2014.08.025)

[4. (Li2015Epigenetic) Xin Li, Jie Yu, Malcolm V. Brock, Qian Tao, James G. Herman, Ping Liang, and Mingzhou Guo. Epigenetic silencing of bcl6b inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-fu. Oncotarget, 6(13):11547–11560, March 2015. URL: http://dx.doi.org/10.18632/oncotarget.3413, doi:10.18632/oncotarget.3413. This article has 25 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.3413)

[5. (Wang2015BCL6B) Weilin Wang, Pengfei Huang, Panyisha Wu, Rong Kong, Jiang Xu, Lufei Zhang, Qifan Yang, Qingsong Xie, Linshi Zhang, Xiaohu Zhou, Linghui Chen, Haiyang Xie, Lin Zhou, and Shusen Zheng. Bcl6b expression in hepatocellular carcinoma and its efficacy in the inhibition of liver damage and fibrogenesis. Oncotarget, 6(24):20252–20265, April 2015. URL: http://dx.doi.org/10.18632/oncotarget.3857, doi:10.18632/oncotarget.3857. This article has 12 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.3857)

[6. (Li2024BCL6Bdependent) Zhonghao Li, Wei Wu, Qiushi Li, Xin Heng, Wei Zhang, Yinghong Zhu, Lin Chen, Ziqi Chen, Mengcheng Shen, Ning Ma, Qingzhong Xiao, and Yi Yan. Bcl6b-dependent suppression of etv2 hampers endothelial cell differentiation. Stem Cell Research &amp; Therapy, July 2024. URL: http://dx.doi.org/10.1186/s13287-024-03832-y, doi:10.1186/s13287-024-03832-y. This article has 1 citations.](https://doi.org/10.1186/s13287-024-03832-y)

[7. (Cai2019Inhibition) Wang-Yu Cai, Ling-Yun Lin, Lin Wang, Li Yang, Guo-Dong Ye, Qiang Zeng, Jia Cheng, Yuan-Yuan Xie, Mao-Li Chen, and Qi-Cong Luo. Inhibition of bcl6b promotes gastric cancer by amplifying inflammation in mice. Cell Communication and Signaling, July 2019. URL: http://dx.doi.org/10.1186/s12964-019-0387-6, doi:10.1186/s12964-019-0387-6. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-019-0387-6)